AbCellera Biologics, Inc. (ABCL)

In the past six months, AbCellera reported its Q3 2025 financial results and appointed Dr. Stephen Quake to its Board of Directors. The company announced a settlement and patent license agreement with Bruker Corporation, which significantly contributed to its Q4 2025 revenue. The first patients were dosed in the Phase 2 portion of its Phase 1/2 clinical trial for ABCL635. AbCellera reported its full-year 2025 business results, beating EPS estimates for Q4 2025, but remained unprofitable. Several firms initiated or reiterated coverage, with positive ratings and target prices. Baker Bros. Advisors increased its stake in AbCellera to 10.8% of outstanding shares. ABCL shares increased by 53.2% since the beginning of the year, with an 18% gain in the week leading up to May 9, 2026. However, individual investors experienced a 10% stock drop in February 2026. AbCellera is scheduled to report its Q1 2026 financial results on May 11, 2026.

AbCellera Biologics' demand is not primarily influenced by traditional product demand seasonality. Demand for its services and pipeline progress are more influenced by R&D cycles in the biotech/pharma industry, clinical trial progress, and strategic partnerships. Stock price seasonality in May refers to stock market patterns rather than underlying demand.

AbCellera Biologics Inc. is a clinical-stage biotechnology company based in Vancouver, Canada, specializing in antibody therapeutics. It operates in the Healthcare sector, utilizing its AI-powered AbCellera Engine for antibody discovery and optimization. The company partners with pharmaceutical firms, retaining downstream economics, and advances its internal pipeline, including ABCL635, ABCL575, ABCL688 and ABCL386. AbCellera has collaborated with over 40 partners on more than 100 antibody drug programs and was the discovery engine behind Eli Lilly's COVID-19 antibodies.

AbCellera Biologics Inc. is headquartered in Vancouver, Canada, with additional locations in Montreal, Canada, Sydney, Australia, and Boston, United States. The company primarily operates in North America and Europe, serving pharmaceutical and biotechnology partners.

AbCellera Biologics' brand reputation has been shaped by its strategic advancements and financial performance. The company has a consensus analyst rating of 'Moderate Buy'. Positive events include pipeline progress, strategic alliances, and a patent settlement. Challenges include financial performance and cash burn, the lack of marketed proprietary drugs, and strategic shift risks.

AbCellera Biologics Inc. has a mixed ownership structure. Institutional investors own approximately 5.25% to 61.4% of the company's stock, with major holders including Baker Bros. Advisors Lp and Capital World Investors. Insiders own approximately 41.17% of the company's stock, with CEO Carl L. G. Hansen being the largest individual shareholder. The general public holds a substantial portion, ranging from 44% to 52.21% of AbCellera Biologics shares.